Posts

Affinity and receptor expression limits tested for LRC-TriCEPS

Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels.

Limits-of-LRC-TriCEPS

Limits-of-LRC-TriCEPS

Details of the assesment see here

Limits-of-LRC-TriCEPS

Affinity and receptor expression

Affinity and receptor expression


Assessment of the limits of the LRC-TriCEPS™ technology


Dualsystems Biotech AG has performed a series of  LRC-TriCEPS™ experiments to determine the range of its applicability. Two cell lines with known receptor expression levels (2`000 and 50`000 receptors per cell, respectively) were used to perform LRC-TriCEPS™ with antibodies of known affinities against the same target receptor. The antibodies were ranging from very high affine (1.00E-10M) to low affine (1.00E-06). In total seven independent LRC-TriCEPS™ experiments were performed. In all experiments insulin was used as a positive control.


Limits-of-LRC-TriCEPS

For all the seven experiments performed the LRC-TriCEPS™ technology was able to identify the known target receptor. Thus, the LRC-TriCEPS™ technology offered by Dualsystems Biotech AG is able to identify receptors of interest with affinities spanning four orders of magnitude at expression levels as low as 2000 receptors per cell.

Further studies with lower affine antibodies or with receptors with lower expression level are needed to determine the lower limit.

Pages

Limits-of-LRC-TriCEPS

Affinity and receptor expression

Affinity and receptor expression


Assessment of the limits of the LRC-TriCEPS™ technology


Dualsystems Biotech AG has performed a series of  LRC-TriCEPS™ experiments to determine the range of its applicability. Two cell lines with known receptor expression levels (2`000 and 50`000 receptors per cell, respectively) were used to perform LRC-TriCEPS™ with antibodies of known affinities against the same target receptor. The antibodies were ranging from very high affine (1.00E-10M) to low affine (1.00E-06). In total seven independent LRC-TriCEPS™ experiments were performed. In all experiments insulin was used as a positive control.


Limits-of-LRC-TriCEPS

For all the seven experiments performed the LRC-TriCEPS™ technology was able to identify the known target receptor. Thus, the LRC-TriCEPS™ technology offered by Dualsystems Biotech AG is able to identify receptors of interest with affinities spanning four orders of magnitude at expression levels as low as 2000 receptors per cell.

Further studies with lower affine antibodies or with receptors with lower expression level are needed to determine the lower limit.